Press release
Atrial Fibrillation Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Atrial Fibrillation Treatment Landscape. Click here to read more @ Atrial Fibrillation Pipeline Outlook [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Atrial Fibrillation Pipeline Report
* In July 2025, Biosense Webster Inc . announced a STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multi-Electrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multi-Electrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF).
* In July 2025, Medtronic Cardiac Rhythm and Heart Failure conducted a study is to demonstrate the efficiency on AT / AF prevention and termination of a new algorithm contained in the Medtronic AT500 Antitachycardia device in patients with conventional pacemaker indications.
* DelveInsight's Atrial Fibrillation pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Atrial Fibrillation treatment.
* The leading Atrial Fibrillation Companies such as Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
* Promising Atrial Fibrillation Pipeline Therapies such as Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
Stay informed about the cutting-edge advancements in Atrial Fibrillation Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Atrial Fibrillation Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atrial Fibrillation Emerging Drugs Profile
* Abelacimab: Anthos Therapeutics, Inc.
Abelacimab is a novel, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease. As a fully human monoclonal antibody, abelacimab is not metabolized via the cytochrome P450 system or as a substrate for P-glycoprotein, meaning the risk for drug-drug interactions is very unlikely. There is also no need to adjust the dose based on age or renal/hepatic status and it can be safely co-administered with antiplatelet agents. Abelacimab is currently being evaluated in several ongoing Phase III clinical trials for patients at risk of dangerous arterial and venous clots, including those with atrial fibrillation and cancer associated thrombosis. In patients with atrial fibrillation, abelacimab is planned to be dosed subcutaneously once-monthly with an autoinjector to maintain near-complete inhibition in a chronic setting. It is also planned to be administered via an initial intravenous (IV) infusion for acute indications requiring immediate onset of action and then followed by subsequent monthly subcutaneous administration. Currently, the drug is in Phase III stage of its development for the treatment of Atrial Fibrillation.
* Etripamil: Milestone Pharmaceuticals Inc.
Etripamil is a fast-acting, intranasal calcium channel blocker developed for the acute management of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Designed for self-administration, it is delivered via a nasal spray, allowing for quick absorption through the nasal mucosa, with onset of action typically within 10 minutes. Etripamil acts rapidly to control heart rate by blocking calcium influx into cardiac cells, helping to slow conduction through the atrioventricular (AV) node. Its short duration of action may reduce the risk of long-term side effects commonly associated with continuous use of traditional antiarrhythmic medications, making it a convenient and potentially safer option for managing sudden AFib episodes. Currently, the drug is in Phase II stage of its development for the treatment of Atrial Fibrillation.
* THRV-1268: Thryv Therapeutics, Inc.
THRV-1268 is a novel and potent inhibitor of the Serum Glucocorticoid Kinase 1 (SGK1). SGK1 is a PI3-kinase-dependent kinase with its expression and activation regulated by several metabolic signaling pathways that are crucial in cardiometabolic diseases. Thryv Therapeutic's first SGK1 inhibitor, LQT-1213, repeatedly demonstrated reductions in QTc interval in pre-clinical studies and in patients with the genetic and acquired Long QT Syndrome. SGK1 has been implicated in various pathological conditions, including QTc prolongation, arrhythmias, fibrosis, and heart failure. SGK1 dysfunction is also linked to cardiometabolic stressors such as obesity and hypertension, which are common comorbidities in heart failure. Genetic and pharmacological inhibition of SGK1 has been demonstrated to have a protective effect in a mouse model of obesity-related atrial fibrillation. In several preclinical models of heart failure, THRV-1268 mitigated the development of heart failure and fibrosis, and reduced heart failure biomarkers associated with adverse changes in hemodynamic and functional cardiovascular outputs. These findings demonstrate the potential of SGK1 inhibition in addressing the pathogenesis of heart failure and related cardiometabolic conditions, including atrial fibrillation. Currently, the drug is in Phase I stage of its development for the treatment of Atrial Fibrillation.
The Atrial Fibrillation Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
* Atrial Fibrillation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.
Get a detailed analysis of the latest innovations in the Atrial Fibrillation pipeline. Explore DelveInsight's expert-driven report today! @ Atrial Fibrillation Unmet Needs [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atrial Fibrillation Companies
Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Atrial Fibrillation Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Atrial Fibrillation Treatment by visiting our website. Stay informed about how we're transforming the future of Cardiovascular Diseases @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Atrial Fibrillation Pipeline Report
* Coverage- Global
* Atrial Fibrillation Companies- Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
* Atrial Fibrillation Pipeline Therapies- Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
* Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Atrial Fibrillation Pipeline on our website @ Atrial Fibrillation Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Atrial Fibrillation: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atrial Fibrillation- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abelacimab: Anthos Therapeutics, Inc.
* Mid Stage Products (Phase II)
* Etripamil: Milestone Pharmaceuticals Inc
* Early Stage Products (Phase I)
* THRV-1268: Thryv Therapeutics, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Atrial Fibrillation Key Companies
* Atrial Fibrillation Key Products
* Atrial Fibrillation- Unmet Needs
* Atrial Fibrillation- Market Drivers and Barriers
* Atrial Fibrillation- Future Perspectives and Conclusion
* Atrial Fibrillation Analyst Views
* Atrial Fibrillation Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atrial-fibrillation-pipeline-outlook-report-2025-key-10-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atrial Fibrillation Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4125276 • Views: …
More Releases from ABNewswire
LOWK3Y Disrupts Luxury Streetwear With a Movement for the Quietly Ambitious - La …
LOWK3Y LLC debuts as a premium lifestyle streetwear brand built for entrepreneurs, creatives, and professionals who let results do the talking. Alongside its launch, the company unveils RARE ACCESS - a first-of-its-kind initiative spotlighting underrepresented talent building legacies behind the scenes, complete with collaborative merchandise drops, media features, and a growing ecosystem designed to reward substance over spectacle.
While most streetwear brands chase hype cycles and influencer endorsements, a new force…
Hard Rock Meets Hard Roast: Foundry Coffee Brings Unapologetic Flavor to Morning …
Foundry, a Las Vegas hard rock band, has launched Hard Rock Roast, a coarse-ground coffee that delivers bold flavors of dark chocolate, brown sugar, and rich molasses. Created by musicians for people who demand intensity in their coffee, the product represents a natural extension of the band's uncompromising artistic vision.
The specialty coffee market is crowded with brands competing on origin stories, processing methods, and carefully curated aesthetics. Into this landscape…
DIVEVOLK Celebrates FPAS 2025 Mobile Devices Champions: Rui Bernardo & Joana Nar …
Portugal - DIVEVOLK [https://www.divevolkdiving.com] proudly congratulates Rui Bernardo and Joana Narciso, the creators behind the 1st Place image in the FPAS 2025 National Underwater Photography Championship (Mobile Devices Category), for capturing this stunning image using the SeaTouch 4 Max underwater housing [https://www.divevolkdiving.com/collections/housing]. Their winning work is a reminder that modern mobile underwater photography isn't just about convenience-it's about community craft: timing, teamwork, and the discipline to wait for a clean…
Proscenic - More Time for Love. Less Time Cleaning
Image: https://www.abnewswire.com/upload/2026/02/c4976d3df5b17be0d7fd75292f2e2a75.jpg
Berlin-Valentine's Day is a time to celebrate love, connection, and the moments that truly matter with our loved ones. At Proscenic [https://www.amazon.de/stores/proscenic/page/D53F96AF-E0B7-4EE6-8493-2B4F1E00BE65], we believe a happy home is a clean, comfortable, and harmonious space where relationships can flourish. This Valentine's Day, we proudly present the Q20Plus Robot Vacuum & Mop, designed to simplify cleaning and give you more time for love.
More Time for Love. Less Time Cleaning.
Image: https://www.abnewswire.com/upload/2026/02/c0e461b3ea82ce1d1cf8b3b47b0fb23d.jpg
The Q20Plus…
More Releases for Atrial
Rising Cardiovascular Disease Rates Drive Growth In Atrial Flutter: A Key Driver …
The Atrial Flutter Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Atrial Flutter Market Size and Its Estimated Growth Rate?
In recent times, the market size for atrial flutter has seen swift growth. The market evaluation is expected to rise from $19.92…
Elevated Prevalence Of Atrial Fibrillation Fuels Growth In The Left Atrial Appen …
What Are the Projected Growth and Market Size Trends for the Left Atrial Appendage Closure Device Market?
The left atrial appendage closure device market will grow from $1.67 billion in 2024 to $2 billion in 2025, at a CAGR of 19.5%. The growth is attributed to the rising prevalence of atrial fibrillation, advancements in stroke prevention strategies, clinical evidence and research, minimally invasive alternatives, and a preference for non-pharmacological options.
The left…
Atrial Fibrillation Surgery Devices Market - Restoring Rhythm, Transforming Live …
Newark, New Castle, USA: The "Atrial Fibrillation Surgery Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Atrial Fibrillation Surgery Devices Market: https://www.growthplusreports.com/report/atrial-fibrillation-surgery-devices-market/8777
This latest report researches the…
Atrial Fibrillation Market - Unveiling the Path to a Steady Heart: Advancements …
Newark, New Castle, USA - new report, titled Atrial Fibrillation Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Atrial Fibrillation market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Atrial Fibrillation market. The report offers an overview of the market, which…
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to…
Atrial Fibrillation Market
Atrial Fibrillation Market is predicted to grow at a double digit CAGR over the forecast period (2017 to 2023). Atrial fibrillation, also denoted as AF, is an irregular or fast heart rhythm. It raises the dangers of chest pain, heart strokes, congestive heart failure, or cardiac discomfort. The typical indications of AF are dizziness, confusion, fainting, or tiredness.
Therapeutic advancements and the burgeoning aged populace also drive the industry. Supportive clinical…
